Table. Variation of clinical and serologic disease activity variables in patients with active lupus treated with belimumab

	N° pts*	Baseline	6 months	12 months	18 months	24 months	30 months	36 months	48 months	p
SLEDAI-2K	458	8.1±3.4	4.9±3.3	3.8±2.7	3.8±3.2	3.5±2.8	2.6±2.8	2.8±2.4	2.7±2.1	<0.0001
Prednisone dosage (mg/day)	458	10.5±8.1	6.7±4.6	5.3±4.7	4.5±4.8	3.8±3.7	3.5±2.9	3.4±4.3	3.4±4.5	<0.0001
DAS-28	309	3.4±1.7	2.5±1.5	2.2±1.4	1.9±1.4	1.7±1.3	1.6±1.5	1.5±1.4	1.4±1.4	<0.0001
CLASI-a	254	3.3±4.7	1.9±3.3	1.1±2.2	0.8±2.1	0.6±1.8	0.6±1.4	0.6±1.4	0.2±0.7	<0.0001
PGA (0-3)	356	1.8±0.6	1.2±0.7	0.8±0.6	0.8±0.7	0.8±0.6	0.7±0.6	0.7±0.6	0.7±0.6	<0.0001
Fatigue (VAS 0-10)	197	5.2±3.0	4.3±2.8	3.3±2.6	2.8±2.7	2.8±2.6	2.5±2.9	2.3±2.7	2.4±2.9	<0.0001
Anti-dsDNA (ELISA, KU/L)	131	230±354	144±217	118±179	107±164	99.2±162	71.5±104	74.4±145	23.0±56.2	<0.006
C3 (mg/dl)	458	50.1±38.8	57.9±41.0	61.2±41.8	59.9±43.1	62.1±41.8	59.2±43.2	64.9±42.6	73.3±45.5	<0.001
C4 (mg/dl)	458	7.7±7.7	10.1±8.5	11.2±9.3	11.2±9.1	11.9±9.3	11.0±9.3	13.8±10.1	13.6±9.7	<0.006
24-h proteinuria (g/day)	77	1.4±1.1	0.8±0.9	0.6±0.6	0.6±0.7	0.6±0.6	0.7±0.8	0.4±0.5	0.6±0.6	0.012

*Number of patients at baseline; p calculated using univariate analysis

SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index-2000; CLASI-a: Cutaneous Lupus erythematosus Area and Severity Index activity; DAS-28: Disease activity score-28 joints; anti-dsDNA: anti-double stranded DNA ELISA: Enzyme-Linked Immunosorbent Assay; pts: patients; CLAI: chemiluminescent immunoassay

Figure. SRI-4 after belimumab in 416 SLE patients

DOI: 10.1136/annrheumdis-2019-eular.3635

FRI0200 REVIEW OF HYDROXYCHLOROQUINE USE AND DEVELOPMENT OF A REGIONAL STRATEGY TO MINIMISE RETINAL TOXICITY

Ursula Laverty¹, Gerard Reid², Julie Silvestri², Adrian Pendleton¹. ¹Musgrave Park Hospital, Belfast, United Kingdom; ²Royal Victoria Hospital, Belfast, United Kingdom

Background: Guidelines from the Royal College of Ophthalmologists in February 2018 were developed for retinal screening for patients on hydroxychloroquine, as recent evidence suggests the risk of retinal toxicity is higher than previously reported. The prevalence of retinal toxicity in long term use appears to be 7.5% and depending on dose and duration of therapy can increase to 20-50% after 20 years of therapy. Risk is increased for patients taking more than 5mg per kg per day of hydroxychloroquine, patients on Tamoxifen and those with renal impairment. The guidelines recommend the use of a standardised referral proforma to help identify patients who are high risk.

Objectives: 1. Audit of Hydroxychloroquine use and retinal screening in the Belfast Health and Social Care Trust (BHSCT)
2. Develop a regional referral proforma and screening service for retinal toxicity

Methods: Patients who were treated with hydroxychloroquine, under the care of a consultant rheumatologist were identified on the database. A proforma was used to aid data collection and patients' electronic records were reviewed. We audited the use of hydroxychloroquine and retinal screening against current Royal College of Ophthalmology (RCO) guidelines. We designed a standardised referral proforma and regional screening strategy in conjunction with ophthalmology colleagues.

Results: There were 151 patients identified on hydroxychloroquine on the database. 40 of these patients had stopped hydroxychloroquine, 2 of which had retinal toxicity. Therefore the rate of retinal toxicity in this sample was 1.3% (2/151).

There were 111 patients who remained on hydroxychloroquine treatment with a female: male ratio of 9:1. Age range was from 22 to 84, with a mean age of 55. There were 44% of patients on hydroxychloroquine for rheumatoid arthritis, 25% had systemic lupus erythematosus, 8% had Sjogrens syndrome, 6% had pallidromic rheumatoid arthritis and 13% had other connective tissue diseases. The majority (79%) of patients were on 200mg hydroxychloroquine daily and 19% were on 400mg daily. 6% of patients had an eGFR<60. No patients were on tamoxifen. 73% of patients were on hydroxychloroquine treatment for over 5 years. Retinal screening was overdue in 64% of patients.

Conclusion: In this sample, only 1.3% of patients had evidence of retinal toxicity, although 64% of patients were overdue retinal screening. We developed a referral proforma and a regional screening strategy in line with RCO guidelines. In order to meet the RCO guidelines, we recognise the need for substantial investment in regional ophthalmology services.

REFERENCES:

[1] Royal College of Ophthalmologists. (2018) Clinical Guidelines. Hydroxychloroquine and Chloroquine Retinopathy: Recommendations on Screening.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.5898

FRI0201 REAL WORLD MEDICATION USE IN INCIDENT SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS PATIENTS

Lin Xie¹, Furaha Kariburyo¹, Janvi Sah¹, Jennifer H. Lofland², Li Nan³.

¹STATinMED Research, Ann Arbor, United States of America; ²Janssen Global Commercial Strategic Organization, Horsham, United States of America; ³Janssen Research and Development, LLC, Horsham, United States of America

Background: Systemic lupus erythematosus (SLE) is an autoimmune disease that causes inflammation in connective tissues and can involve multiple organs systems. Lupus nephritis (LN) is an inflammatory kidney disease caused by SLE. There is a gap in the literature regarding the standard of care in SLE and LN patients.

Objectives: This study generated real world medication use among SLE and LN patients.

Methods: This retrospective study used data from two large administrative databases in the US: Truven Health MarketScan[®] and Optum[®] databases to identify adult patients (≥18 years of age) with ≥2 medical claims on different dates for SLE or LN diagnoses from 01JAN2013-31DEC2015. SLE was identified using the International Classification of Diseases, 9th and 10th Revision, Clinical Modification [ICD-9-CM] codes (710.0) OR ICD-10-CM (M32.10-M32.19, 32.8, 32.9). LN was captured as a subset of SLE using [ICD-9-CM: 710.0 AND (581.81 or 582.81 or 583.81); OR (ICD-10-CM:M32.14)]. The first SLE or LN diagnosis was designated as the index date. Patients were required to have continuous health plan enrollment for 1 year pre-index date (baseline period) and 1 year post-index date (follow-up period) and no prior SLE/LN diagnosis claims or belimumab medical/prescription claim during the baseline period to ensure incident patients were captured. The Truven Health MarketScan[®] and Optum[®] databases were pooled together and duplicates were identified and retained in MarketScan[®] only. Patient demographics and clinical characteristics during the baseline period were assessed. SLE treatment used during the follow-up period was evaluated and the proportion of patients that used SLE medications and average number of medical/prescription claims (#Rx) for each medication were provided.

Results: A total of 31,345 patients were identified including 30,086 SLE and 1,259 LN patients. Key results are shown in Table 1. The mean age was 52.7 years for SLE and 48.3 years for LN patients. Over 80% of the patients were female, with a mean Charlson Comorbidity Index (CCI) score of 1.1 and 1.8 for SLE and LN patients respectively. The most common comorbidities at baseline were hypertension and infections. Corticosteroids (SLE= 58.3%, #Rx=4.5; LN=66.2%, #Rx=6.5) and hydroxychloroquine (SLE=43.4%, #Rx=5.8; LN=40.7% #Rx=6.2) were the most commonly used SLE medications during 1-year follow up period. Approximately 2% of patients used biologics including belimumab (SLE=1.1%, #Rx=8.8; LN=1.4%, #Rx=8.3) and rituximab (SLE=0.9%, #Rx=4.2; LN=2.1%, #Rx=4.0).